DBV Technologies SA confirms initiation of Viaskin Peanut global phase III trial
Tuesday, June 23, 2015
DBV Technologies SA Confirms planned initiation of Viaskin peanut global phase III clinical trial in children following end-of-phase II meeting with FDA and PIP approval by EMA.
* Based on regulatory consultations, company plans to initiate a global phase III trial with Viaskin Peanut in Q4 2015
* Says additional development plans for Viaskin Peanut in younger and older patients will be discussed with FDA in H2 2015
* Clinical data from CoFar6 using Viaskin Peanut, is also expected to be reported in late 2015 or early 2016
reuters.com
